Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|July 24, 2012

ABUS Effective Screening Alternative to MRI

Automated breast ultrasound (ABUS) is as effective as MRI in breast cancer screening in women with dense breast tissue, researchers say.

Automated breast ultrasound (ABUS) is as effective as MRI in breast cancer screening in women with dense breast tissue, show results of a study published in the July/August issue of Journal of Diagnostic Medical Sonography. In addition, the ABU’s short examination time and ease of use may make it a practical choice in many situations.

For this preliminary study, researchers from Nova Southeastern University in Winter Springs, Fla., assessed 24 asymptomatic women with more than 50 percent breast density on digital mammography. Each woman underwent an ABUS exam, which was followed a week later by a 3D contrast breast MRI. After comparing the two examinations, the researchers found 15 malignant tumors and nine benign pathologies.

Comparable diagnostic reliability was observed between the ABUS and the MRI in differentiating benign from malignant breast lesions based on similar morphologic criteria.

ABUS is cleared for diagnostic use, but not specifically for screening in women with dense breasts. ABUS does have disadvantages, including the inability to compress the breast tissue and the ability to view tissue or lesion vascularity. However, advantages to the procedure include that it is not invasive and that it is simple to use with less technical training than an MRI requires, perhaps making it more viable to screen larger groups of people.

The authors concluded that ABUS is a promising cost-effective adjunct diagnostic modality to MRI in the evaluation women with increased breast density by digital mammography.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.